Navigation Links
Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Enhance Efficiency and Scale-up of its Malaria Vaccine Manufacturing Process
Date:9/15/2009

ROCKVILLE, Md., Sept. 16 /PRNewswire-USNewswire/ -- Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is $1.99 million. Subject to satisfactory progress by Sanaria, continued funding for a third year will bring the total to nearly $3 million. This new funding will facilitate efforts to increase the efficiency and scale-up of manufacturing and release processes to the levels required for Phase 3 clinical testing, licensure, and commercial launch of Sanaria(TM) PfSPZ, Sanaria's attenuated whole parasite malaria sporozoite vaccine.

Sanaria(TM) PfSPZ Vaccine entered Phase 1 clinical trials of safety and efficacy at the Naval Medical Research Center and the University of Maryland School of Medicine's Center for Vaccine Development in the spring of 2009. Since 2003, peer-reviewed NIAID SBIR grants have provided Sanaria with over $17 million in financial support.

About Sanaria(TM) PfSPZ Vaccine

Sanaria(TM)( )PfSPZ Vaccine consists of live sporozoite-stage Plasmodium falciparum parasites weakened (attenuated) by exposure to radiation. Such sporozoites, delivered to human volunteers by the bite of infected mosquitoes, have been shown to confer protection against malaria. Sanaria has developed novel technologies and facilities to successfully translate research findings from a handful of volunteers receiving mosquito-administered sporozoites to a bona fide vaccine that can be clinically tested and conventionally administered to hundreds of millions of recipients. Although live, attenuated pathogens are commonly used to vaccinate against many viral and bacterial diseases, the Sanaria(TM)( )PfSPZ Vaccine is unique among vaccines designed to prevent malaria. For the first time, an immunogen conferring high levels of protection against malaria has been formulated as a stable, injectable vaccine candidate that meets regulatory standards.

About Sanaria Inc.

Sanaria Inc. was founded in 2003. The company's primary mission is to develop and commercialize attenuated whole-parasite malaria vaccines that confer high-level, long-lasting protection against Plasmodium falciparum, the parasite responsible for most of the malaria-associated severe illness and death worldwide. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is http://www.sanaria.com.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. Such statements include the assessment of the vaccine candidate, the expectations for immunity of the vaccine, and belief concerning the measure of success. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the Company's ability to raise sufficient funds, the regulatory approval process, dependence on third-parties, clinical trials results, and the ability to commercialize the vaccine.

For further information contact:

Media- Adam Richman 301.770.3222, Investors- Robert Thompson 240.403.2750


'/>"/>
SOURCE Sanaria Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant
2. KV Pharmaceutical Receives Stockholder Action by Written Consent
3. gloStreams gloEMR Version 5.0 Receives 08 CCHIT Certification
4. Center for AIDS Intervention Research Medical receives $11.16 million NIH grant
5. Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
6. Digestive Care, Inc. Receives Complete Response Letter from FDA for PANCRECARB(R) (pancrelipase)
7. COLD-FX(R) Receives Highest Sports Certification in North America
8. Project Lifesaver International Receives Federal Assistance for the Missing Alzheimers Patient Assistance Program
9. RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
10. UM receives grant to support graduate students in the family nurse practitioner program
11. Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology: